MedWatch

Danish company prepares to take the psoriasis market by storm – seeks FDA approval

The privately-owned company MC2 Therapeutics will launch their newly developed psoriasis treatment to the American market next year, if all goes well. The company’s product has beaten a Leo Pharma alternative when directly compared in clinical trials, and the FDA will now decide whether to approve the treatment.

"We have peace of mind, because it feels like we are doing the right things. We are constantly building up our case," says Jesper J. Lange, Administrative Drector for MC2 Therapeutics. | Photo: MC2 Therapeutics / PR

MC2 Therapeutics, which is based in Hørsholm, has quietly developed a product that could have a significant impact on the American market for psoriasis treatment.

The Danish biotech company has recently submitted a 39,500-page long application to the American health authority, Food & Drug Administration (FDA), applying for permission to market their product Wynzora.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Further reading

Related articles

Latest news

See all jobs